Guidelines for mono, double and triple antithrombotic therapy

11Citations
Citations of this article
50Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Guidelines for antithrombotic therapy are complex, especially if a patient has several indications that require antithrombotic therapy. In general, no patient should receive lifelong double or triple antithrombotic therapy. In this overview, we outline the most common indications for mono, double and triple antithrombotic therapy; the preferred antithrombotic therapy and the recommended duration of therapy. Both antiplatelet therapy and therapeutic anticoagulation therapy with vitamin K antagonists or direct oral anticoagulants were included. European guidelines were used or, if no European guidelines were available, the Dutch guidelines were used.

Cite

CITATION STYLE

APA

Van Uden, R. C. A. E., Houtenbos, I., Griffioen-Keijzer, A., Odekerken, D. A. M., Van Den Bemt, P. M. L. A., & Becker, M. L. (2021, November 1). Guidelines for mono, double and triple antithrombotic therapy. Postgraduate Medical Journal. BMJ Publishing Group. https://doi.org/10.1136/postgradmedj-2020-138938

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free